Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC25A | P30304 | 1/20 | 0.56 |
| ▸ | CDC25B | P30305 | 1/20 | 0.56 |
| ▸ | OSBP | P22059 | 3/20 | 0.46 |
| ▸ | OSBP2 | Q969R2 | 3/20 | 0.46 |
| ▸ | GPR183 | P32249 | 5/20 | 0.43 |
| ▸ | NPC1L1 | Q9UHC9 | 5/20 | 0.43 |
| ▸ | CRYAB | P02511 | 1/20 | 0.41 |
| ▸ | HMGCR | P04035 | 1/20 | 0.41 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.41 |
| ▸ | ITGAV | P06756 | 1/20 | 0.41 |
| ▸ | RORC | P51449 | 1/20 | 0.41 |
| ▸ | SREBF2 | Q12772 | 1/20 | 0.41 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.41 |
| ▸ | VDR | P11473 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13392701 | 1.00 | CDC25A (0.56) | CDC25ACDC25BOSBPOSBP2GPR183 | |
| SCHEMBL4899038 | 0.92 | CDC25A (0.49) | CDC25ACDC25BOSBPOSBP2GPR183 | |
| SCHEMBL16317442 | 0.92 | CDC25A (0.52) | CDC25ACDC25BOSBPOSBP2GPR183 | |
| SCHEMBL14005478 | 0.92 | CDC25A (0.49) | CDC25ACDC25BOSBPOSBP2GPR183 | |
| SCHEMBL4911035 | 0.92 | CDC25A (0.49) | CDC25ACDC25BOSBPOSBP2GPR183 | |
| SCHEMBL14005504 | 0.92 | CDC25A (0.49) | CDC25ACDC25BOSBPOSBP2GPR183 | |
| SCHEMBL4896073 | 0.91 | CDC25A (0.48) | CDC25ACDC25BOSBPOSBP2GPR183 | |
| SCHEMBL4896078 | 0.91 | CDC25A (0.48) | CDC25ACDC25BOSBPOSBP2GPR183 | |
| SCHEMBL14005425 | 0.91 | CDC25A (0.48) | CDC25ACDC25BOSBPOSBP2GPR183 | |
| SCHEMBL14030819 | 0.91 | CDC25A (0.48) | CDC25ACDC25BOSBPOSBP2GPR183 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100069339-A1 | NOVEL METHOD OF TREATMENT OF MALE SUB-FERTILITY | BIOXELL S.P.A. (IT) | 2010-03-18 | — | — | US | disclosed |
| EP-0980354-B1 | VITAMIN D3 ANALOGS WITH BIS C-20 SIDE CHAINS | HOFFMANN LA ROCHE (CH) | 2002-06-19 | — | — | EP | disclosed |
| US-6030962-A | FOR TREATING OSTEOPOROSIS, HYPERPARATHYROIDISM AND AUTOIMMUNE DISEASES | SYNTTEX (U.S.A.) INC. (US) | 2000-02-29 | — | — | US | disclosed |
| EP-0980354-A2 | VITAMIN D 3? ANALOGS WITH BIS C-20 SIDE CHAINS | F. HOFFMANN-LA ROCHE AG (CH) | 2000-02-23 | — | — | EP | disclosed |
| US-6008209-A | INDUCING INHIBITION OF CELL PROLIFERATION IN A BREAST TUMOR BY ADMINISTERING AN ANTITUMOR AGENT | HOFFMANN-LA ROCHE INC. (US) | 1999-12-28 | — | — | US | disclosed |
| WO-1998049138-A2 | VITAMIN D3 ANALOGS WITH BIS C-20 SIDE CHAINS | F.HOFFMANN-LA ROCHE AG (CH) | 1998-11-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069339-A1 | NOVEL METHOD OF TREATMENT OF MALE SUB-FERTILITY | CYP27B1, CYP2R1, SHBG | CDC25A 3455/4885CDC25B 3024/4885OSBP 565/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.